Director/PDMR Shareholding
05 Diciembre 2023 - 10:00AM
Director/PDMR Shareholding
DXS INTERNATIONAL PLC
Notification of Director / PDMR Dealing
The Board of DXS International plc (the
“Company”), the AQSE Growth Market quoted clinical decision support
developer and supplier of clinical decision support systems has
received notification that on 4 December 2023 Mr Bob Sutcliffe
purchased a total of 400,000 Ordinary Shares in the Company at a
price of 2.5p per share on behalf of himself and others.
Mr Sutcliffe’s interest in the transaction was
acquiring 180,000 Ordinary Shares. He has also transferred 200,000
DXS shares to his adult daughters. Following these transactions Mr
Sutcliffe and his wife’s interest in DXS Ordinary Shares is 833,386
Ordinary Shares representing 1.3% of the issued share capital of
the Company.
|
1 |
Details of the person discharging managerial
responsibilities / person closely associated |
|
a) |
Name |
Robert Sutcliffe |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Chairman |
|
b) |
Initial notification /Amendment |
Initial |
|
3 |
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor |
|
a) |
Name |
DXS INTERNATIONAL PLC |
|
b) |
LEI |
2138001R1KEUWTXEVJ44 |
|
4 |
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted |
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.33p each |
|
|
|
|
Identification code |
ISIN GB00B2Q6HZ92 |
|
|
|
|
b) |
Nature of the transaction |
Issue of new shares |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
2.5p |
180,000 |
|
|
|
|
|
|
|
|
d) |
Aggregated information |
|
|
|
|
|
- Aggregated volume |
|
|
|
|
|
- Price |
|
|
|
|
|
e) |
Date of the transaction |
4 December 2023 |
|
f) |
Place of the transaction |
Aquis Stock Exchange |
The Directors of DXS International plc accept
responsibility for this announcement.
Enquiries:
| David
Immelman (Chief
Executive)DXS International plc |
01252 719800david@dxs-systems.com |
| Wrecclesham
HouseWrecclesham RoadFarnhamSurreyGU10 4PS |
|
|
www.dxs-systems.co.uk |
|
| Corporate
Advisor |
|
| David
PapworthCity & Merchant |
0207 101 7676 |
| Corporate
Broker |
|
| Hybridan
LLPClaire Louise Noyce |
020 3764 2341 |
Note to Editors:
DXS International presents up to date treatment
guidelines and recommendations, from Clinical Commissioning Groups
and other trusted NHS sources, to doctors, nurses and pharmacists
in their workflow and during the patient consultation. This
effective clinical decision support ultimately translates to
improved healthcare outcomes delivered more cost effectively which
should significantly contribute towards the NHS achieving its
projected efficiency savings.
DXS (AQSE:DXSP)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
DXS (AQSE:DXSP)
Gráfica de Acción Histórica
De May 2023 a May 2024
